EA202000299A1 - ANTICORONAVIRUS FOR COMBINATION THERAPY FOR COVID-19 (SARS-CoV-2) - Google Patents

ANTICORONAVIRUS FOR COMBINATION THERAPY FOR COVID-19 (SARS-CoV-2)

Info

Publication number
EA202000299A1
EA202000299A1 EA202000299A EA202000299A EA202000299A1 EA 202000299 A1 EA202000299 A1 EA 202000299A1 EA 202000299 A EA202000299 A EA 202000299A EA 202000299 A EA202000299 A EA 202000299A EA 202000299 A1 EA202000299 A1 EA 202000299A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cov
sars
drug
covid
combination therapy
Prior art date
Application number
EA202000299A
Other languages
Russian (ru)
Inventor
Андрей Александрович ИВАЩЕНКО
Александр Васильевич ИВАЩЕНКО
Николай Филиппович САВЧУК
Алёна Александровна Иващенко
Владимир Григорьевич ЛОГИНОВ
Михаил ТОПР
Original Assignee
Андрей Александрович ИВАЩЕНКО
Александр Васильевич ИВАЩЕНКО
Николай Филиппович САВЧУК
Алёна Александровна Иващенко
Владимир Григорьевич ЛОГИНОВ
Михаил ТОПР
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Андрей Александрович ИВАЩЕНКО, Александр Васильевич ИВАЩЕНКО, Николай Филиппович САВЧУК, Алёна Александровна Иващенко, Владимир Григорьевич ЛОГИНОВ, Михаил ТОПР filed Critical Андрей Александрович ИВАЩЕНКО
Publication of EA202000299A1 publication Critical patent/EA202000299A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к применению нового противокоронавирусного средства для комбинированной терапии COVID-19 (SARS-CoV-2). Средство включает в терапевтически эффективном количестве и соотношении апротинин (АПР) или лекарственный препарат на его основе и ингибитор репликации SARS-CoV-2. Лекарственный препарат на основе апротинина предпочтительно выбирается из группы, представляющей собой Апротекс, Веро-Наркап, Ингитрил, Контрикал, Контрисел, Трасилол, Ингипрол, Апротимбин, Гордокс, Контривен, Трасколан или Аэрус. В качестве ингибитора репликации SARS-CoV-2 может быть использован фавипиравир (ФВП) или Ремдесевир (РМД) или лекарственный препарат на их основе. Лекарственный препарат на основе фавипиравира предпочтительно выбирается из группы, представляющей собой Авиган, Фавилавир, Авифавир, Коронавир или Фабифлю. Применение нового противокоронавирусного средства приводит к новому и синергетическому эффекту, позволяет значительно сократить сроки лечения и уменьшить риск появления нежелательных побочных явлений.The invention relates to the use of a new anti-coronavirus agent for combination therapy of COVID-19 (SARS-CoV-2). The agent includes a therapeutically effective amount and ratio of aprotinin (APR) or a drug based on it and an inhibitor of SARS-CoV-2 replication. The aprotinin-based drug is preferably selected from the group consisting of Aprotex, Vero-Narcap, Ingitril, Contrical, Contrisel, Trasilol, Ingiprol, Aprotimbin, Gordox, Contriven, Traskolan or Aerus. Favipiravir (FVP) or Remdesavir (RMD) or a drug based on them can be used as an inhibitor of SARS-CoV-2 replication. The favipiravir drug is preferably selected from the group consisting of Avigan, Favilavir, Avifavir, Coronavir or Fabiflu. The use of a new anti-coronavirus agent leads to a new and synergistic effect, can significantly reduce the duration of treatment and reduce the risk of unwanted side effects.

EA202000299A 2020-08-21 2020-10-22 ANTICORONAVIRUS FOR COMBINATION THERAPY FOR COVID-19 (SARS-CoV-2) EA202000299A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2020127969A RU2742116C1 (en) 2020-08-21 2020-08-21 Anti-coronavirus agent for covid-19 combination therapy (sars-cov-2)

Publications (1)

Publication Number Publication Date
EA202000299A1 true EA202000299A1 (en) 2022-02-28

Family

ID=74554613

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202000299A EA202000299A1 (en) 2020-08-21 2020-10-22 ANTICORONAVIRUS FOR COMBINATION THERAPY FOR COVID-19 (SARS-CoV-2)

Country Status (2)

Country Link
EA (1) EA202000299A1 (en)
RU (1) RU2742116C1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2711080C2 (en) * 2015-06-15 2020-01-15 Олег Петрович Жирнов Combined aerosol composition based on protease inhibitors and preparation thereof

Also Published As

Publication number Publication date
RU2742116C1 (en) 2021-02-02

Similar Documents

Publication Publication Date Title
EA202190630A1 (en) COMBINED THERAPY METHODS
EA202090955A1 (en) METHODS OF USING EHMT2 INHIBITORS IN TREATMENT OR PREVENTION OF BLOOD DISORDERS
MX367541B (en) Papd5 and papd7 inhibitors for treating a hepatitis b infection.
EA202092343A1 (en) TREATMENT OF PURULENT HYDRADENITIS WITH THE USE OF JAK INHIBITORS
EA201200762A1 (en) Application of F2-Alpha Prostaglandins and Analogues for the Healing of Cornea Damage and Conjunctiva
EA201890146A1 (en) METHODS OF TREATMENT OF SOLID TUMORS USING COMBINED THERAPY BY mTOR INHIBITOR IN THE FORM OF NANOPARTICLES
MX2024000271A (en) Shp2 inhibitor and use thereof.
MX2019012884A (en) Combination therapy.
MX2020008258A (en) Pediatric niraparib formulations and pediatric treatment methods.
CA2474479A1 (en) Composition for inhalation
EP4249431A3 (en) Compositions and methods for treating diseases or disorders using extended release nitric oxide releasing solutions
EA202192122A1 (en) COMPOUNDS WITH FERROPTOSE-INDUCING ACTIVITY AND METHODS FOR THEIR APPLICATION
MX2021007330A (en) Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor.
EA202191170A1 (en) COMBINED THERAPY FOR TREATMENT OF HEMATOLOGICAL DISEASES
MX2021011230A (en) Subcutaneous administration of nanoparticles comprising an mtor inhibitor and albumin for treatment of diseases.
CO2022000426A2 (en) Plasma kallikrein inhibitors
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
EA202190057A1 (en) SOLUBILIZED APIRAZES, METHODS AND APPLICATION
EA202000298A1 (en) ANTICORONAVIRUS AGENT FOR COMBINATION THERAPY OF COVID-19 (SARS-CoV-2) AND METHOD OF TREATMENT
EA202000299A1 (en) ANTICORONAVIRUS FOR COMBINATION THERAPY FOR COVID-19 (SARS-CoV-2)
EA202193190A1 (en) COMPOSITION INCLUDING PRIDOPIDINE AND ITS ANALOGUE FOR THE TREATMENT OF HUNTINGTON'S DISEASE AND ITS SYMPTOMS
EA202190798A1 (en) ROTAMERIC ISOMERS OF 4-ALKYL-5-HETEROARYL-3H-1,2-DITHIOL-3-THIONES
CL2021003303A1 (en) Treatment for synucleinopathies.
PL423672A1 (en) Pharmaceutical composition containing zebularine and a therapeutic agent for regeneration of wounds
MX2023004516A (en) Use of pridopidine and analogs for the treatment of anxiety and depression.